5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cardiopulmonary O
reactions O
, O
including O
fatalities O
. O

Always O
have O
resuscitation O
equipment O
and O
trained O
personnel O
readily O
available O
( O
5.1 O
) O
* O
Anaphylactoid O
reactions O
( O
5.2 O
) O
5.1 O
Cardiopulmonary O
Reactions O
Serious O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
fatalities B-NonOSE_AE
have O
occurred O
uncommonly O
during O
or O
shortly O
following O
administration O
of O
ultrasound O
contrast O
agents O
, O
including O
Lumason O
. O

These O
reactions O
typically O
occurred O
within O
30 O
minutes O
of O
administration O
. O

The O
risk O
for O
these O
reactions O
may O
be O
increased O
among O
patients O
with O
unstable O
cardiopulmonary B-Not_AE_Candidate
conditions I-Not_AE_Candidate
( O
acute B-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
artery O
syndromes I-Not_AE_Candidate
, O
worsening B-Not_AE_Candidate
or O
unstable O
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
serious O
ventricular B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
) O
. O

Always O
have O
cardiopulmonary O
resuscitation O
personnel O
and O
equipment O
readily O
available O
prior O
to O
Lumason O
administration O
and O
monitor O
all O
patients O
for O
acute O
reactions O
. O

The O
reported O
reactions O
that O
may O
follow O
the O
administration O
of O
ultrasound O
contrast O
agents O
include O
: O
fatal O
cardiac B-OSE_Labeled_AE
or O
respiratory O
arrest I-OSE_Labeled_AE
, O
shock B-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
symptomatic B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
( O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
supraventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
and O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
) O
, O
hypertension B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
hypoxia B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
distress I-OSE_Labeled_AE
, O
stridor B-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
and O
convulsions B-OSE_Labeled_AE
. O

5.2 O
Anaphylactoid O
Reactions O
Anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
such O
as O
skin B-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
throat B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
or O
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
have O
uncommonly O
been O
observed O
following O
the O
injection O
of O
Lumason O
. O

These O
reactions O
may O
occur O
in O
patients O
with O
no O
history O
of O
prior O
exposure O
to O
sulfur O
hexafluoride O
lipid O
containing O
microspheres O
. O

5.3 O
Systemic B-OSE_Labeled_AE
Embolization I-OSE_Labeled_AE
In O
patients O
with O
right B-Not_AE_Candidate
- I-Not_AE_Candidate
to I-Not_AE_Candidate
- I-Not_AE_Candidate
left I-Not_AE_Candidate
, O
bi-directional O
, O
or O
transient O
right-to-left O
cardiac I-Not_AE_Candidate
shunts I-Not_AE_Candidate
, O
some O
intravenously O
injected O
sulfur O
hexafluoride O
lipid O
containing O
microspheres O
may O
bypass O
filtering O
by O
the O
lung O
and O
directly O
enter O
the O
arterial O
circulation O
. O

Occlusion B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
microcirculation I-OSE_Labeled_AE
by O
these O
microspheres O
may O
result O
in O
tissue B-NonOSE_AE
ischemia I-NonOSE_AE
. O

Lumason O
is O
only O
for O
intravenous O
administration O
; O
do O
not O
administer O
Lumason O
by O
intra-arterial O
injection O
. O

5.4 O
High O
Mechanical O
Index O
High O
ultrasound B-NonOSE_AE
mechanical I-NonOSE_AE
index I-NonOSE_AE
values I-NonOSE_AE
may I-NonOSE_AE
cause I-NonOSE_AE
microsphere I-NonOSE_AE
cavitation I-NonOSE_AE
or I-NonOSE_AE
rupture I-NonOSE_AE
and O
lead O
to O
ventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
. O

Additionally O
, O
end-systolic O
triggering O
with O
high O
mechanical O
indices O
has O
been O
reported O
to O
cause O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
. O

